1. Abeona Therapeutics appoints Mohamad Tabrizi as Chief Business Officer. 2. Tabrizi's experience includes strategic development and venture capital leadership. 3. He previously executed 20 deals at Nektar and significant fundraising activities. 4. Appointment aims to enhance operational efficiency and drive strategic partnerships. 5. Abeona develops gene therapies; ZEVASKYN is a notable product for RDEB treatment.
FAQ
Why Bullish?
The appointment of a seasoned executive like Tabrizi can improve business development and partnerships, historically tied to stock price improvements.
How important is it?
The leadership change signifies a strategic pivot which could lead to new opportunities and partnerships, enhancing investor confidence.
Why Long Term?
Fostering strategic partnerships and operational efficiencies typically affects stock performance over a longer period, as results materialize from these efforts.
Abeona Therapeutics Appoints Mohamad Tabrizi as Chief Business Officer
CLEVELAND, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) has announced a key appointment to its leadership team. Mohamad Tabrizi, M.S., M.B.A., has been named as the Senior Vice President and Chief Business Officer (CBO). In this pivotal role, Mr. Tabrizi will direct the company’s corporate strategy and business development initiatives, ensuring operational efficiency across the organization.
Expertise and Leadership
Vish Seshadri, Chief Executive Officer of Abeona, expressed enthusiasm about Mr. Tabrizi's extensive background, stating, “Mohamad brings a wealth of experience in strategic planning and business development. We look forward to leveraging his extensive network and proven expertise to optimize our operations and guide Abeona toward value-creating partnerships.”
Prior Experience
Before joining Abeona, Mr. Tabrizi played significant roles in venture capital, serving as a General Partner and Managing Director at Pandect Bioventures and the Berkeley Catalyst Fund. His responsibilities encompassed leading investment activities, managing portfolios, and holding operational leadership positions within portfolio companies, including positions as Chief Executive Officer of Azkarra Therapeutics and Interim Chief Financial Officer at Circle Pharma.
Impressive Track Record
Mr. Tabrizi's commercial insight is founded on a robust scientific basis, having completed research fellowships and associate roles at renowned institutions such as the Howard Hughes Medical Institute and Stanford University Medical School. His previous experience includes a noteworthy track record in corporate development at Nektar Therapeutics where he executed 20 transactions and established collaborations with leading pharmaceutical companies like AstraZeneca, Bristol-Myers Squibb, Pfizer, Merck, and Amgen between 2007 and 2017.
Educational Background
Mr. Tabrizi holds an M.B.A. from Cornell University, an M.S. in Biological Sciences from Stanford University, and a B.S. in Genetics from the University of California, Davis.
About Abeona Therapeutics Inc.
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company dedicated to developing cell and gene therapies for serious diseases. The company's flagship product, ZEVASKYN® (prademagene zamikeracel), is recognized as the first autologous cell-based gene therapy for treating wounds in adults and pediatric patients suffering from recessive dystrophic epidermolysis bullosa (RDEB). The company operates a fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio, responsible for commercial production of ZEVASKYN.
Research and Development Focus
Abeona’s development portfolio also includes adeno-associated virus (AAV)-based gene therapies tailored for ophthalmic diseases that display a high unmet medical need. The firm is currently evaluating its novel, next-generation AAV capsids for various serious conditions.
Contact Information
For further inquiries or information, please contact:
- Investor and Media: Greg Gin, VP, Investor Relations and Corporate Communications, Abeona Therapeutics
- Investor Relations: Lee M. Stern, Meru Advisors
Forward-Looking Statements
This press release may contain forward-looking statements that involve risks and uncertainties. Factors that could lead to actual results differing materially from those indicated include the company's ability to successfully commercialize ZEVASKYN, market dynamics, regulatory approvals, and changes in financial conditions. The company undertakes no obligation to revise forward-looking statements following the date of this press release.